# A First-in-Human Study of QY211 Gel in Adult Subjects

> **NCT05843422** · PHASE1 · UNKNOWN · sponsor: **E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.** · enrollment: 56 (estimated)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** 0.1% QY211 Gel or placebo
- **DRUG:** 0.3% QY211 Gel or placebo
- **DRUG:** 0.8% QY211 Gel or placebo
- **DRUG:** 1.5% QY211 Gel or placebo

## Key facts

- **NCT ID:** NCT05843422
- **Lead sponsor:** E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-03-01
- **Primary completion:** 2024-10-23
- **Final completion:** 2024-10-23
- **Target enrollment:** 56 (ESTIMATED)
- **Last updated:** 2023-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05843422

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05843422, "A First-in-Human Study of QY211 Gel in Adult Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05843422. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*